Skip to main content
SpringerLink
Log in

Ureteral Obstruction After Endoscopic Treatment of Vesicoureteral Reflux: Does the Type of Injected Bulking Agent Matter?

  • Pediatric Urology (D Weiss, Section Editor)
  • Published:
Current Urology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Endoscopic injection of bulking agents for the treatment of vesicoureteral reflux (VUR) has become a therapeutic alternative to antibiotic prophylaxis and ureteral reimplantation. Although considered as a safe and efficient procedure, several studies have reported cases of ureteral obstruction (UO) after endoscopic correction of VUR. This review article evaluates the present VUR literature to estimate the incidence of UO following endoscopic injection of different substances, while also discussing the impact of injection technique and implant volume.

Recent Findings

Twenty-five publications were identified that provided detailed information on 64 females and 32 males (age range, 7 months–48 years) that developed UO after endoscopic treatment of VUR using dextranomer/hyaluronic acid (Dx/HA), polyacrylate polyalcohol (PP), polydimethylsiloxane (PDMS), calcium hydroxyapatite (CaHA), polytetrafluoroethylene (PTFE), or collagen. There was some variation in the reported incidence of UO among these materials: Dx/HA (0.5–6.1%), PP (1.1–1.6%), PDMS (2.5–10.0%), CaHA (1.0%), and PTFE (0.3%). Postoperative UO was described following subureteric transurethral injection (STING), intraureteric hydrodistension implantation technique (HIT), combined HIT/STING and double HIT. The injected volume ranged widely, also depending on the type of bulking agent: Dx/HA (0.3–3.0 mL), PP (0.3–1.2 mL), PDMS (1.0–2.2 mL), CaHA (0.4–0.6 mL), and PTFE (1.5–2.0 mL). The timing of UO varied from immediately after the procedure to 63 months. Over half of patients showed asymptomatic hydroureteronephrosis on follow-up imaging, whereas the remaining presented with symptoms of acute UO or fever.

Summary

UO remains a rare complication after endoscopic correction of VUR, generally reported in less than 1% of treated cases, which appears to be independent of the injected substance, volume, and technique. However, long-term follow-up is recommended as asymptomatic or delayed UO can occur, potentially leading to deterioration of renal function.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Williams G, Fletcher JT, Alexander SI, Craig JC. Vesicoureteral reflux. J Am Soc Nephrol. 2008;19:847–62.

    Article  CAS  Google Scholar 

  2. Sargent MA. What is the normal prevalence of vesicoureteral reflux? Pediatr Radiol. 2000;30:587–93.

    Article  CAS  Google Scholar 

  3. Diamond DA, Mattoo TK. Endoscopic treatment of primary vesicoureteral reflux. N Engl J Med. 2012;366:1218–26.

    Article  CAS  Google Scholar 

  4. Sung J, Skoog S. Surgical management of vesicoureteral reflux in children. Pediatr Nephrol. 2012;27:551–61.

    Article  Google Scholar 

  5. Cara-Fuentes G, Gupta N, Garin EH. The RIVUR study: a review of its findings. Pediatr Nephrol. 2015;30:703–6.

    Article  Google Scholar 

  6. Peters CA, Skoog SJ, Arant BS Jr, Copp HL, Elder JS, Hudson RG, et al. Summary of the AUA guideline on management of primary vesicoureteral reflux in children. J Urol. 2010;184:1134–44.

    Article  Google Scholar 

  7. Hayn MH, Smaldone MC, Ost MC, Docimo SG. Minimally invasive treatment of vesicoureteral reflux. Urol Clin North Am. 2008;35:477–88.

    Article  Google Scholar 

  8. Routh JC, Inman BA, Reinberg Y. Dextranomer/hyaluronic acid for pediatric vesicoureteral reflux: systematic review. Pediatrics. 2010;125:1010–9.

    Article  Google Scholar 

  9. Puri P, Kutasy B, Colhoun E, Hunziker M. Single center experience with endoscopic subureteral dextranomer/hyaluronic acid injection as first line treatment in 1,551 children with intermediate and high grade vesicoureteral reflux. J Urol. 2012;188:1485–9.

    Article  Google Scholar 

  10. Hsieh MH, Madden-Fuentes RJ, Lindsay NE, Roth DR. Treatment of pediatric vesicoureteral reflux using endoscopic injection of hyaluronic acid/dextranomer gel: intermediate-term experience by a single surgeon. Urology. 2010;76:199–203.

    Article  Google Scholar 

  11. Läckgren G, Wåhlin N, Sköldenberg E, Stenberg A. Long-term follow-up of children treated with dextranomer/hyaluronic acid copolymer for vesicoureteral reflux. J Urol. 2001;166:1887–92.

    Article  Google Scholar 

  12. Ormaechea M, Ruiz E, Denes E, Gimenez F, Dénes FT, Moldes J, et al. New tissue bulking agent (polyacrylate polyalcohol) for treating vesicoureteral reflux: preliminary results in children. J Urol. 2010;183:714–7.

    Article  CAS  Google Scholar 

  13. Vandersteen DR, Routh JC, Kirsch AJ, Scherz HC, Ritchey ML, Shapiro E, et al. Postoperative ureteral obstruction after subureteral injection of dextranomer/hyaluronic Acid copolymer. J Urol. 2006;176:1593–5.

    Article  CAS  Google Scholar 

  14. Kirlum HJ, Stehr M, Dietz HG. Late obstruction after subureteral collagen injection. Eur J Pediatr Surg. 2006;16:133–4.

    Article  Google Scholar 

  15. Mevorach RA, Hulbert WC, Rabinowitz R, Kennedy WA, Kogan BA, Kryger JV, et al. Results of a 2-year multicenter trial of endoscopic treatment of vesicoureteral reflux with synthetic calcium hydroxyapatite. J Urol. 2006;175:288–91.

    Article  Google Scholar 

  16. Al-Hunayan AA, Kehinde EO, Elsalam MA, Al-Mukhtar RS. Outcome of endoscopic treatment for vesicoureteral reflux in children using polydimethylsiloxane. J Urol. 2002;168:2181–3.

    Article  CAS  Google Scholar 

  17. Puri P, Granata C. Multicenter survey of endoscopic treatment of vesicoureteral reflux using polytetrafluoroethylene. J Urol. 1998;160:1007–11.

    Article  CAS  Google Scholar 

  18. Perović S, Smoljanic Ž, Šćepanović D, Vukadinović V. Ureteral obstruction caused by subureteral Teflon injection. Pediatr Surg Int. 1991;6:283–6.

    Article  Google Scholar 

  19. Snodgrass WT. Obstruction of a dysmorphic ureter following dextranomer/hyaluronic acid copolymer. J Urol. 2004;171:395–6.

    Article  Google Scholar 

  20. •• Papagiannopoulos D, Rosoklija I, Cheng E, Yerkes E. Delayed obstruction with asymptomatic loss of renal function after dextranomer/hyaluronic Acid copolymer (Deflux) injection for vesicoureteral reflux: a close look at a disturbing outcome. Urology. 2017;101:63–6 A series of 3 cases where Deflux was used in off-label fashion, resulting in delayed UO and loss of renal function.

    Article  Google Scholar 

  21. Rubenwolf PC, Ebert AK, Ruemmele P, Rösch WH. Delayed-onset ureteral obstruction after endoscopic dextranomer/hyaluronic acid copolymer (Deflux) injection for treatment of vesicoureteral reflux in children: a case series. Urology. 2013;81:659–62.

    Article  Google Scholar 

  22. Zemple RP, Potretzke AM, Kryger JV. Delayed onset ureteral obstruction following Deflux® injection for vesicoureteral reflux. J Pediatr Urol. 2012;8:e23–6.

    Article  CAS  Google Scholar 

  23. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Open Med. 2009;3:e123–30.

    PubMed  PubMed Central  Google Scholar 

  24. Serrano Durba A, Bonillo García MA, Moragues Estornell F, Domínguez Hinarejos C, Sanguesa C, Martínez Verduch M, et al. Vesicoureteric reflux endoscopic treatment complications in childhood. Actas Urol Esp. 2006;30:170–4.

    Article  CAS  Google Scholar 

  25. Alizadeh F, Mazdak H, Khorrami MH, Khalighinejad P, Shoureshi P. Postoperative ureteral obstruction after endoscopic treatment of vesicoureteral reflux with polyacrylate polyalcohol copolymer (Vantris®). J Pediatr Urol. 2013;9:488–92.

    Article  Google Scholar 

  26. García-Aparicio L, Rodo J, Palazon P, Martín O, Blázquez-Gómez E, Manzanares A, et al. Acute and delayed vesicoureteral obstruction after endoscopic treatment of primary vesicoureteral reflux with dextranomer/hyaluronic acid copolymer: why and how to manage. J Pediatr Urol. 2013;9:493–7.

    Article  Google Scholar 

  27. Alenezi H, Alhazmi H, Trbay M, Neel KF. Endoscopic correction of vesicoureteral reflux in children with a solitary kidney: the risk of obstruction. J Pediatr Urol. 2013;9:1166–9.

    Article  Google Scholar 

  28. Şencan A, Yıldırım H, Özkan KU, Uçan B, Karkıner A, Hoşgör M. Late ureteral obstruction after endoscopic treatment of vesicoureteral reflux with polyacrylate polyalcohol copolymer. Urology. 2014;84:1188–93.

    Article  Google Scholar 

  29. •• Ben-Meir D, Bahouth Z, Halachmi S. Late-onset Uretero-vesical Junction obstruction following endoscopic injection of bulking material for the treatment of vesico-ureteral reflux. Urology. 2017;101:60–2 A retrospective review of nine patients who developed late-onset UO following endoscopic treatment of VUR. The proposed mechanisms are gradual increase in ureterovesical junction resistance and ineffective peristalsis.

    Article  Google Scholar 

  30. • Okawada M, Murakami H, Tanaka N, Ogasawara Y, Lane GJ, Okazaki T, et al. Incidence of ureterovesical obstruction and Cohen antireflux surgery after Deflux® treatment for vesicoureteric reflux. J Pediatr Surg. 2018;53:310–2 A retrospective series of 339 patients with VUR who received endoscopic Deflux treatment. UO was detected in eight cases suggesting that this complication may be more frequent than previously reported.

    Article  Google Scholar 

  31. •• Chertin B, Mele E, Kocherov S, Zilber S, Gerocarni Nappo S, et al. What are the predictive factors leading to ureteral obstruction following endoscopic correction of VUR in the pediatric population? J Pediatr Urol. 2018;14:538.e1–7 A retrospective study of 2495 patients who underwent endoscopic correction of VUR. There were no differences in incidence of UO and histopathological changes between Deflux and Vantris.

    Article  CAS  Google Scholar 

  32. Seifert HH, Mazzola B, Zellweger T, Ruszat R, Muller A, Burkhalter F, et al. Ureteral obstruction after dextranomer/hyaluronic acid copolymer injection for treatment of secondary vesicoureteral reflux after renal transplantation. Urology. 2006;68:203.e17–9.

    Google Scholar 

  33. Onol FF, Tarcan T, Tinay I, Kotiloğlu E, Simşek F. Kidney loss due to periureteral fibrosis and ureteral obstruction secondary to migration of subureterically injected calcium hydroxylapatite. J Pediatr Urol. 2006;2:503–8.

    Article  Google Scholar 

  34. Zaccara A, Castagnetti M, Beniamin F, Rigamonti W. Late onset ureteric obstruction after endoscopic subureteric injection of calcium hydroxyapatite for primary vesicoureteric reflux. Urology. 2007;70:811.e1–3.

    Article  Google Scholar 

  35. Arlen AM, Pakalniskis BL, Cooper CS. Asymptomatic chronic partial obstruction of a normal ureter following dextranomer/hyaluronic acid copolymer (Deflux®) injection for grade I vesicoureteral reflux. J Pediatr Urol. 2012;8:e27–30.

    Article  Google Scholar 

  36. Abbo O, Bouali O, Beauval JB, Moscovici J, Galinier P. Distal and late ureteral obstruction: a rare complication following dextranomer/hyaluronic acid injection for vesicoureteral reflux in children. Prog Urol. 2012;22:192–4.

    Article  CAS  Google Scholar 

  37. Nseyo U, Mancini JG, Wiener JS. Symptomatic bilateral delayed partial ureteral obstruction after bilateral endoscopic correction of vesicoureteral reflux with dextranomer/hyaluronic acid polymer. Urology. 2013;81:184–7.

    Article  Google Scholar 

  38. Aaronson DS, Siddiqui SA, Reinberg Y, Baskin LS. Relative contraindication to endoscopic subureteral injection for vesicoureteral reflux: congenital refluxing megaureter with distal aperistaltic segment. Urology. 2008;71:616–9.

    Article  Google Scholar 

  39. Kempf C, Winkelmann B, Roigas J, Querfeld U, Müller D. Severe complications after endoscopic injection of polydimethylsiloxane for the treatment of vesicoureteral reflux in early childhood. Scand J Urol Nephrol. 2010;44:347–53.

    Article  Google Scholar 

  40. Mazzone L, Gobet R, González R, Zweifel N, Weber DM. Ureteral obstruction following injection of dextranomer/hyaluronic acid copolymer: an infrequent but relevant complication. J Pediatr Urol. 2012;8:514–9.

    Article  Google Scholar 

  41. Chung JM, Park CS, Lee SD. Postoperative ureteral obstruction after endoscopic treatment for vesicoureteral reflux. Korean J Urol. 2015;56:533–9.

    Article  Google Scholar 

  42. O’Donnell B, Puri P. Treatment of vesicoureteric reflux by endoscopic injection of Teflon. Br Med J. 1984;289:7–9.

    Article  Google Scholar 

  43. Kirsch AJ, Perez-Brayfield M, Smith EA, Scherz HC. The modified sting procedure to correct vesicoureteral reflux: improved results with submucosal implantation within the intramural ureter. J Urol. 2004;171:2413–6.

    Article  Google Scholar 

  44. Kirsch AJ, Arlen AM. Evaluation of new Deflux administration techniques: intraureteric HIT and Double HIT for the endoscopic correction of vesicoureteral reflux. Expert Rev Med Devices. 2014;11:439–46.

    Article  CAS  Google Scholar 

  45. Baybikov R, Sizonov V, Bondarenko S, Dolgov B, Dubrov V, Kagantsov I, et al. Do the type of bulking agents and injection method have any influence on the incidence of ureteral obstruction by endoscopic treatment of reflux? European Society for Paediatric Urology. 2015. https://www.espu.org/members/previous-events-abstracts. Accessed 20 Apr 2019.

  46. Kirsch AJ, Perez-Brayfield MR, Scherz HC. Minimally invasive treatment of vesicoureteral reflux with endoscopic injection of dextranomer/hyaluronic acid copolymer: the Children’s Hospitals of Atlanta experience. J Urol. 2003;170:211–5.

    Article  Google Scholar 

  47. Sorensen MD, Koyle MA, Cowan CA, Zamilpa I, Shnorhavorian M, Lendvay TS. Injection volumes of dextranomer/hyaluronic acid are increasing in the endoscopic management of vesicoureteral reflux. Pediatr Surg Int. 2010;26:509–13.

    Article  Google Scholar 

  48. Routh JC, Ashley RA, Sebo TJ, Vandersteen DR, Slezak J, Reinberg Y. Histopathological changes associated with dextranomer/hyaluronic acid injection for pediatric vesicoureteral reflux. J Urol. 2007;178:1707–10.

    Article  Google Scholar 

  49. Stenberg A, Larsson E, Läckgren G. Endoscopic treatment with dextranomer-hyaluronic acid for vesicoureteral reflux: histological findings. J Urol. 2003;169:1109–13.

    Article  CAS  Google Scholar 

  50. Palagiri AV, Dangle PP. Distal ureteral calcification secondary to deflux injection: a reality or myth? Urology. 2011;77:1217–9.

    Article  Google Scholar 

  51. Noe HN. Calcification in a Deflux bleb thought to be a ureteral calculus in a child. J Pediatr Urol. 2008;4:88–9.

    Article  Google Scholar 

  52. • Friedmacher F, Colhoun E, Puri P. Endoscopic Injection of dextranomer/hyaluronic acid as first line treatment in 851 consecutive children with high grade vesicoureteral reflux: efficacy and long-term results. J Urol. 2018;200:650–5 A prospective study of 851 patients who underwent endoscopic correction of high-grade VUR with no cases of postoperative UO.

    Article  CAS  Google Scholar 

  53. Ben-Meir D, Morgenstern S, Sivan B, Efrat R, Livne PM. Histology proved malpositioning of dextranomer/hyaluronic acid in submucosal ureter in patients after failed endoscopic treatment of vesicoureteral reflux. J Urol. 2012;188:258–61.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. National Children’s Research Centre, Our Lady’s Children’s Hospital, Dublin, Ireland

    Florian Friedmacher & Prem Puri

  2. Department of Pediatric Surgery, The Royal London Hospital, Whitechapel Road, London, E1 1FR, UK

    Florian Friedmacher

Authors
  1. Florian Friedmacher
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prem Puri
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Florian Friedmacher.

Ethics declarations

Conflict of Interest

Florian Friedmacher and Prem Puri each declare no potential conflicts of interest.

Human and Animal Rights and Informed Consent

This review article does not contain any studies with human participants or animals performed by the author.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Pediatric Urology

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Friedmacher, F., Puri, P. Ureteral Obstruction After Endoscopic Treatment of Vesicoureteral Reflux: Does the Type of Injected Bulking Agent Matter?. Curr Urol Rep 20, 49 (2019). https://doi.org/10.1007/s11934-019-0913-5

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11934-019-0913-5

Keywords

Search

Navigation